Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis

References

• Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329–1340.
   PubMed Web of Science ®Google Scholar
• Song P, Rudan D, Wang M, et al. National and subnational estimation of the prevalence of peripheral artery disease (PAD) in China: a systematic review and meta-analysis. J Glob Health. 2019;9(1):010601.
   PubMed Web of Science ®Google Scholar
• Tian SL, Tian XK, Han QF, et al. Peripheral arterial disease predicts overall and cardiovascular mortality in peritoneal dialysis patients. Ren Fail. 2012;34(8):1010–1014.
   PubMed Web of Science ®Google Scholar
• Tian SL, Tian XK, Han QF, et al. Presence of peripheral arterial disease predicts loss of residual renal function in incident CAPD patients. Perit Dial Int. 2012;32(1):67–72.
   PubMed Web of Science ®Google Scholar
• Rochette L, Meloux A, Rigal E, et al. The role of osteoprotegerin in the crosstalk between vessels and bone: its potential utility as a marker of cardiometabolic diseases. Pharmacol Ther. 2018;182:115–132.
   PubMed Web of Science ®Google Scholar
• Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000;192(4):463–474.
   PubMed Web of Science ®Google Scholar
• Hosbond SE, Poulsen TS, Diederichsen AC, et al. Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scand Cardiovasc J. 2012;46(4):203–211.
   PubMed Web of Science ®Google Scholar
• Esteghamati A, Aflatoonian M, Rad MV, et al. Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes. Arch Cardiovasc Dis. 2015;108(8–9):412–419.
   PubMed Web of Science ®Google Scholar
• Niu Y, Zhang W, Yang Z, et al. Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes. BMC Cardiovasc Disord. 2015;15(1):86.
   PubMedGoogle Scholar
• Nascimento MM, Hayashi SY, Riella MC, et al. Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3–5 chronic kidney disease. Braz J Med Biol Res. 2014;47(11):995–1002.
   PubMed Web of Science ®Google Scholar
• Demir P, Erdenen F, Aral H, et al. Serum Osteoprotegerin levels related with cardiovascular risk factors in Chronic Kidney Disease. J Clin Lab Anal. 2016;30(6):811–817.
   PubMed Web of Science ®Google Scholar
• Chen YC, Hsu BG, Ho CC, et al. Elevated serum osteoprotegerin may predict peripheral arterial disease after kidney transplantation: a single-center prospective cross-sectional study in Taiwan. PeerJ. 2017;5:e3847.
   PubMed Web of Science ®Google Scholar
• Avila M, Mora C, Mexican Collaborative Group, et al. Osteoprotegerin is the strongest predictor for progression of arterial calcification in peritoneal dialysis patients. Am J Nephrol. 2017;46(1):39–46.,
   PubMed Web of Science ®Google Scholar
• Hsu BG, Lee CJ, Yang CF, et al. High serum resistin levels are associated with peripheral artery disease in the hypertensive patients. BMC Cardiovasc Disord. 2017;17(1):80.
   PubMedGoogle Scholar
• Ferreira AC, Macedo FY. A review of simple, non-invasive means of assessing peripheral arterial disease and implications for medical management. Ann Med. 2010;42(2):139–150.
   PubMed Web of Science ®Google Scholar
• O’Hare AM, Glidden DV, Fox CS, et al. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999. Circulation. 2004;109(2000):320–323.
   PubMedGoogle Scholar
• Arroyo D, Betriu A, Valls J, et al. Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study. Nephrol Dial Transplant. 2017;32(3):513–520.
   PubMed Web of Science ®Google Scholar
• Lin CS, Chen SJ, Sung CC, et al. Hemodialysis is associated with increased peripheral artery occlusive disease risk among patients with end-stage renal disease: a nationwide population-based cohort study. Medicine. 2015;94(28):e1164.
   PubMed Web of Science ®Google Scholar
• Lee CC, Wu CJ, Chou LH, et al. Peripheral artery disease in peritoneal dialysis and hemodialysis patients: single-center retrospective study in Taiwan. BMC Nephrol. 2012;13(1):100.
   PubMedGoogle Scholar
• Kuang DW, Li CL, Kuok UI, et al. Prevalence and risk factors associated with peripheral artery disease in elderly patients undergoing peritoneal dialysis. Vasc Health Risk Manag. 2012;8:581–586.
   PubMedGoogle Scholar
• Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260–1268.
   PubMed Web of Science ®Google Scholar
• Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106(10):1192–1194.
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Siasos G, Maniatis K, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol. 2013;167(5):1924–1928.
   PubMed Web of Science ®Google Scholar
• Ustundag M, Orak M, Guloglu C, et al. The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: determination of stroke subtype, severity and mortality. J Int Med Res. 2011;39:780–789.
   PubMed Web of Science ®Google Scholar
• Ziegler S, Kudlacek S, Luger A, et al. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis. 2005;182(1):175–180.
   PubMed Web of Science ®Google Scholar
• Schwenger V, Morath C, Salava A, et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol . 2006;17(1):199–207.
   PubMed Web of Science ®Google Scholar
• Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62(5):1524–1538.
   PubMed Web of Science ®Google Scholar
• Zemel D, Krediet RT. Cytokine patterns in the effluent of continuous ambulatory peritoneal dialysis: relationship to peritoneal permeability. Blood Purif. 1996;14(2):198–216.
   PubMed Web of Science ®Google Scholar
• Davenport C, Mahmood WA, Forde H, et al. The effects of insulin and liraglutide on asteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes. Eur J Endocrinol. 2015;173(1):53–61.
   PubMed Web of Science ®Google Scholar
• Park JS, Cho MH, Nam JS, et al. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2011;164(1):69–74.
   PubMed Web of Science ®Google Scholar
• Davenport C, Ashley DT, O’Sullivan EP, et al. The effects of atorvastatin on arterial stiffness in male patients with type 2 diabetes. J Diabetes Res. 2015;2015:1–6.
   Web of Science ®Google Scholar
• Kadoglou NP, Kottas G, Lampropoulos S, et al. Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-reductase inhibitor) therapy. Clin Drug Investig. 2014;34(3):165–171.
   PubMed Web of Science ®Google Scholar